As part of the agreement, Abbott will provide Bigfoot with the next generation of its FreeStyle Libre glucose sensing technology. Bigfoot will utilize this technology in the development of the first-ever personalized, user-friendly systems intended to optimize insulin delivery without the need for fingerstick calibration of a glucose sensor.
“Diabetes is increasing at record rates globally. There is a significant demand for tools that are intuitive and easy to use to help people take control of this complicated, challenging condition, but innovation in this area has been slow,” said Jared Watkin, senior vice president, Diabetes Care, Abbott. “Together with Bigfoot, we are challenging conventional methods of diabetes management by bringing together our expertise in superior glucose monitoring technology with a best-in-class insulin delivery system that is designed with the patient in mind. This will fundamentally transform the way diabetes is managed.”
All people with Type 1 diabetes, and nearly one third of people with Type 2 diabetes, must inject insulin to manage their glucose – that’s more than 6 million peopleii in the U.S. alone. Bigfoot and Abbott both share a vision to simplify the use of diabetes management systems for these insulin users: a goal that moves beyond technology and into accessibility and cost reduction for individuals, their health care providers and payers.
News from our partners.
